You are here: Industry Insights > Big Pharma

News List

Chief digital officers land at Big Pharma—cue tech transformations, test innovations, corner offices fiercepharma
December 25, 2018
What’s in a title? In the case of chief digital officers, it's a trend. The transformative tech value-generators are all the rage these days, and the pharma industry is no exception.
Chief digital officers land at Big Pharma—cue tech transformations, test innovations, corner offices fiercepharma
December 20, 2018
What’s in a title? In the case of chief digital officers, it's a trend. The transformative tech value-generators are all the rage these days, and the pharma industry is no exception.
AbbVie's 96% tax break: Big Pharma reaps huge benefit from Trump tax reform fiercepharma
November 05, 2018
AbbVie is known as one of the largest pharma beneficiaries of the U.S. tax reform. Just how much has it gained? In the first nine months of 2018, the Illinois pharma has paid just 4.5% of the income taxes it shelled out the same period last year.
Big Pharma's antibody drugs for asthma show benefits but cost 50% too much: ICER fiercepharma
September 27, 2018
New antibody-based treatments are better than traditional drugs for moderate to severe asthma, but they still cost too much, a U.S. drug cost watchdog says. More than 50% too much, in fact.
The top 10 drugmakers of 2024 fiercepharma
September 26, 2018
Big Pharma will get bigger, much bigger, over the next several years, with the companies vying to grow their sales in a range of established and emerging therapeutic areas, notably cancer and immunology.
Universal flu vaccine biotech seeks Big Pharma partnership for phase 3 testing: CEO fiercevaccines
July 23, 2018
Problems with seasonal flu shots have been well documented, and now U.K. biotech Imutex believes it has the next big advance for flu vaccine technology.
Takeda to vault into Big Pharma with $62B Shire buyout—and megamerger cuts are on the way fiercepharma
May 09, 2018
After weeks of bidding, the Japanese drugmaker agreed to shell out $62 billion on the rare disease specialist, 46% cash, 54% stock—roughly the same terms Takeda disclosed when it announced its fifth bid. The deal will vault Takeda into the top 10 pharma c

Previous page 1 2 Next page